Enrollment in the pivotal phase 3 trial of EGP-437, a treatment candidate for noninfectious anterior uveitis, has been completed, EyeGate Pharmaceuticals announced in a press release.
A total of 250 patients in the United States were enrolled in the double-masked, randomized, positive-controlled trial, which will assess the safety and efficacy of EGP-437.
The trial’s primary efficacy endpoint is the proportion of subjects with an anterior chamber cell count of zero at day 14, the release said. Patients will be given three treatments of either EGP-437 iontophoresis treatment or a placebo
Uncategorized